Lineagen, Inc., a Salt Lake City, Utah-based developer of innovative genomic tests and services for the screening, evaluation and diagnosis of complex disorders and diseases including autism spectrum disorders and others, has received an additional $5m investment from PrairieGold Venture Partners.
This financing brings the total amount raised by the company in its Series A financing round to $10.8m. In December 2007, Lineagen held a $5.8m first close. The Series A round included support from Sanderling Ventures, vSpring Capital and Mesa Verde Venture Partners.
The new capital will support further development of Linegen’s lead autism program and its commercial service launch, expected for September 2010.
In conjunction with the financing, Mike Jerstad, Partner of PrairieGold Venture Partners, will join the company’s board of directors.
FinSMEs
30/08/2010